Zobrazeno 1 - 10
of 332
pro vyhledávání: '"Jiang A"'
Autor:
Marek Trněný, Kathryn Humphrey, Nathalie A. Johnson, Sven de Vos, Gilles Salles, Farheen Mir, Richard Greil, Yanwen Jiang, Elizabeth Punnoose, Robin Gasiorowski, Arijit Sinha, Su Y. Kim, Caterina Patti, Emma Clark, Andrew D. Zelenetz, Jean-François Larouche, Nathalie Spielewoy, Divya Samineni, Alexandra Bazeos, Franck Morschhauser, Pierre Feugier, Pieternella J. Lugtenburg, Árpád Illés, Ian W. Flinn
Publikováno v:
Blood, 137(5), 600-609. American Society of Hematology
Blood
Blood
The phase 2 CAVALLI (NCT02055820) study assessed efficacy and safety of venetoclax, a selective B-cell lymphoma-2 (Bcl-2) inhibitor, with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in first-line (1L) diffuse la
Autor:
Ying-Jun Chang, Qiao-Zhu Zeng, Ye-Jun Wu, Lan-Ping Xu, Qian Jiang, Yun He, Xiao-Hui Zhang, Yi Liu, He-Bing Zhou, Jing-Wen Wang, Hao Jiang, Qiu-Sha Huang, Hui Liu, Jia Feng, Wen-Sheng Wang, Xiao-Jun Huang, Xiao-Lu Zhu, Hai-Xia Fu
Publikováno v:
Blood. 139(3)
The study aimed to compare the efficacy and safety of all-trans retinoic acid (ATRA) plus low-dose rituximab (LD-RTX) with LD-RTX monotherapy in corticosteroid-resistant or relapsed immune thrombocytopenia (ITP) patients. Recruited patients were rand
Autor:
Toby A. Eyre, Hande H. Tuncer, Rajesh Kamalakar, Daniel Dingfeng Jiang, John N. Allan, Paul M. Barr, Anthony R. Mato, Danielle M. Brander, Nnadozie Emechebe, Lindsey E. Roeker, Matthew S. Davids, Chaitra S. Ujjani, Dandan Zheng, Beenish S Manzoor, Rebecca Burne, Annie Guerin, German Pena, Kavita Sail, Barbara Eichhorst, Jennifer R. Brown, Rajat Bannerji, Irina Pivneva, Alan P Skarbnik, Simon Sharmokh
Publikováno v:
Blood. 136:19-22
Introduction: Venetoclax has demonstrated deep responses and sustained progression-free survival and is well tolerated in patients (pts) with previously untreated or relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic leukemia (C
Autor:
Morten Tulstrup, Jonas Abrahamsson, Ramneek Gupta, Chuang Jiang, Hui Zhang, Lisa Lyngsie Hjalgrim, Kjeld Schmiegelow, Jacob Nersting, Bendik Lund, Jukka Kanerva, Marie Grosjean, Takaya Moriyama, Olafur G. Jonsson, Benjamin Ole Wolthers, Kathrine Grell, Goda Vaitkeviciene, Stine Nygaard Nielsen, Kaie Pruunsild, Ulrik Malthe Overgaard, Jun J. Yang, Rikke Linnemann Nielsen, Petter Quist-Paulsen
Publikováno v:
Blood
Methotrexate (MTX) during maintenance therapy is essential for curing acute lymphoblastic leukemia (ALL), but dosing strategies aiming at adequate treatment intensity are challenged by interindividual differences in drug disposition. To evaluate gene
Autor:
Stephan Stilgenbauer, Michele Porro Lurà, Karl-Anton Kreuzer, Yanwen Jiang, Barbara Eichhorst, Eugen Tausch, Michael Hallek, Sandra Robrecht, Jasmin Bahlo, Can Zhang, Hartmut Döhner, Christof Schneider, Johannes Bloehdorn, Anna-Maria Fink, William Schary, Daniel Mertens, Maneesh Tandon, Kirsten Fischer, Anna Dolnik, Kathryn Humphrey, Othman Al-Sawaf, Matthias Ritgen, Lars Bullinger, Michael Kneba
Publikováno v:
Blood. 135:2402-2412
Genetic parameters are established prognostic factors in chronic lymphocytic leukemia (CLL) treated with chemoimmunotherapy, but are less well studied with novel compounds. We assessed immunoglobulin heavy variable chain (IGHV) mutation status, commo
Autor:
Yizhou Jiang, Abhinav Deol, Lianqing Zheng, Sattva S. Neelapu, Jenny J. Kim, Nancy L. Bartlett, John M. Rossi, Ira Braunschweig, Olalekan O. Oluwole, Javier Munoz, David B. Miklos, Caron A. Jacobson, Frederick L. Locke
Publikováno v:
Blood. 135:2106-2109
Neelapu and colleagues report a post hoc subgroup analysis from the ZUMA-1 trial of chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B cell lymphoma. In comparison with younger patients, those ≥65 years old have sim
Autor:
Anna-Maria Fink, Maneesh Tandon, Othman Al-Sawaf, Eugen Tausch, Michaela Patz, Stephan Stilgenbauer, Jasmin Bahlo, Kirsten Fischer, Esther Lilienweiss, Barbara Eichhorst, William Schary, Matthias Ritgen, Sandra Robrecht, Yanwen Jiang, Michael Hallek, Karl-Anton Kreuzer
Publikováno v:
Blood. 135:866-870
Autor:
Yiping Zhu, Qun Hu, Hui Zhang, Hua Jiang, Jiaoyang Cai, Xin Tian, Runming Jin, Changda Liang, Hui Jiang, Ju Gao, Cheng Cheng, Minghua Yang, Jingyan Tang, Alex Wing Kwan Leung, Yongjun Fang, Chunfu Li, Xiaowen Zhai, Shuhong Shen, Jie Yu, Li Zhang, Ningling Wang, Xiaofan Zhu, Chi Kong Li, Ching-Hon Pui, Shaoyan Hu, Kaili Pan, Xuedong Wu, Lirong Sun, Xiuli Ju, Jun J. Yang
Publikováno v:
Blood
To identify the prognostic factors that are useful to improve central nervous system (CNS) control in children with acute lymphoblastic leukemia (ALL), we analyzed the outcome of 7640 consecutive patients treated on Chinese Children’s Cancer Group
Autor:
Arnon P. Kater, Clemens Mellink, Yanwen Jiang, Marco Montillo, Barbara Eichhorst, Sarit Assouline, Javier de la Serna, Carolyn Owen, Tadeusz Robak, Marcus Lefebure, Peter Hillmen, Michelle Boyer, Thomas J. Kipps, Brenda Chyla, John F. Seymour, Ulrich Jaeger, James D'Rozario, Cameron Wilson, Guillaume Cartron, Jenny Wu, Nicole Lamanna
Publikováno v:
Blood. 136:19-21
Introduction: The randomized Phase III MURANO study (NCT02005471) compared fixed-duration VenR with standard bendamustine-rituximab (BR) in R/R CLL. Deep responses with uMRD were associated with superior progression-free survival (PFS) of VenR vs BR
Autor:
Lihong Shou, Shenxian Qian, He Huang, Huixian Hu, Yi Zhao, Xiaoyan Han, Wei Jiang, Gaofeng Zheng, Qingxiao Chen, Enfan Zhang, Jiaping Fu, Jingsong He, Donghua He, Wenhua Jiang, Yi Li, Zhen Cai
Publikováno v:
Blood. 138:4761-4761
Background Research has demonstrated that histone deacetylase (HDAC) is overexpressed in plasma cells. Panobinostat was the first HDAC inhibitor (HDACi) approved by FDA for the treatment of patients with relapse and refractory multiple myeloma (RRMM)